ReviewCurrent opinion in immunology2026
Amyloid precursor protein is a subunit of microglial Hv1 channels.
Review in Current opinion in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Voltage-gated proton channels (Hv1) are key regulators of microglial activation, coupling proton extrusion to reactive oxygen species production, cellular pH homeostasis, and pro-inflammatory signaling. Dysregulated Hv1 activity exacerbates neuroinflammation and contributes to a range of central nervous system pathologies. Our recent work shows that proton channels in microglia are formed by the co-assembly of Hv1 pore-forming subunits and amyloid precursor protein (APP). APP, and its C99 transmembrane fragment, assemble with Hv1 to enhance channel activity, altering gating kinetics, modifying pharmacological properties, and amplifying inflammatory mediator release from microglia. Importantly, Alzheimer's disease-associated APP mutations further potentiate Hv1 activity, providing a mechanistic link between genetic risk factors and microglial dysfunction, offering APP-Hv1 as a new therapeutic target for neuroinflammatory disease. This review summarizes current views of microglial Hv1 function and highlights that Hv1, long thought to operate as homodimers despite exhibiting varied attributes in native cells, exhibits functional diversity through accessory subunit incorporation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.